Affimed N.V. (NASDAQ: AFMD) is a clinical-stage biotechnology company focused on the discovery and development of multi-specific antibody-based therapies designed to harness both innate and adaptive immune cells for the treatment of cancer. The company’s proprietary ROCK® platform enables the design and engineering of bispecific, trispecific and tetraspecific antibodies that engage natural killer (NK) cells, macrophages and T cells to selectively target tumor cells and potentiate immune-mediated tumor eradication. Affimed’s pipeline includes lead candidates such as AFM13, an NK cell engager targeting CD30-positive lymphomas, and AFM24, an EGFR-directed macrophage engager, both of which have advanced into clinical trials.
In addition to its internally developed pipeline, Affimed has established collaborations and partnerships aimed at accelerating the advancement of its novel therapies. Strategic alliances with leading pharmaceutical and biotechnology companies provide access to complementary expertise, resources and expanded clinical trial networks. These partnerships underscore Affimed’s commitment to developing next-generation immuno-oncology solutions and delivering meaningful improvements in patient outcomes across a variety of oncologic indications.
Founded in 2000 and headquartered in Heidelberg, Germany, Affimed also maintains operations in Redwood City, California and Boston, Massachusetts, reflecting its global footprint across Europe and North America. The company’s research and development teams work in concert across multiple sites to conduct preclinical studies, manufacturing process development and early- to late-stage clinical trials. Affimed’s presence in major biotechnology hubs facilitates access to world-class scientific talent, regulatory expertise and collaborative opportunities within the broader oncology community.
Affimed’s leadership team is comprised of seasoned professionals with deep experience in oncology drug development, regulatory affairs and commercial strategy. Under the guidance of Chief Executive Officer Patrick Groothuis and a management group that includes experts in clinical development, translational science and regulatory policy, Affimed continues to build on its proprietary technology platform. The company remains focused on advancing its therapeutic candidates through key clinical milestones and ultimately delivering innovative treatment options for patients with cancer.
AI Generated. May Contain Errors.
Free AFMD Stock Alerts